Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.50 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293480 | 0.79 | PTPN1 (0.68) | GSK3BPTPN1KDM4ESMN1; SMN2 | |
| SCHEMBL1293647 | 0.78 | BACE1 (0.47) | GSK3BPTPN1BACE1KDM4ESMN1; SMN2 | |
| SCHEMBL1758852 | 0.78 | GSK3B (0.42) | GSK3BPTPN1BACE1 | |
| SCHEMBL27887117 | 0.77 | HSD17B1 (0.46) | HSD17B14SMN1; SMN2LRRK2 | |
| SCHEMBL12647391 | 0.77 | KDM4E (0.40) | HSD17B14BACE1KDM4ESMN1; SMN2LRRK2 | |
| SCHEMBL689331 | 0.75 | GSK3B (0.83) | GSK3BPTPN1KDM4ESMN1; SMN2 | |
| SCHEMBL1293407 | 0.74 | HSD17B1 (0.46) | HSD17B14BACE1SMN1; SMN2LRRK2 | |
| SCHEMBL1459295 | 0.73 | MGAM (0.61) | PTPN1KDM4ESMN1; SMN2 | |
| Bromide SCHEMBL7478921 | 0.71 | MGAM (0.59) | PTPN1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15993663 | 0.71 | MGAM (0.59) | PTPN1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | GSK3B 619/4885PTPN1 1848/4885HSD17B14 210/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | GSK3B 1377/4885PTPN1 2043/4885HSD17B14 343/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GSK3B 519/4885PTPN1 1524/4885HSD17B14 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.